ARX 1.79% 55.0¢ aroa biosurgery limited

poor TELA bio results, page-3

  1. 295 Posts.
    lightbulb Created with Sketch. 61
    I'm only a new shareholder, but it seems to me that ARX's main issue is that our revenue is too dependent on TELA, and they are a small - and seemingly half-baked - company. ARX is trying to navigate away from this by ramping up the in-house sales team - but that takes time.

    Brian Ward is heavily invested in ARX, and it's his baby, so I think he has our best interests in mind. But he chose the wrong partner in TELA, and that is something that must be addressed at some point. Hopefully, TELA will still meet their guidance of near 30% growth, but it's hard to see how based on these recent results?
 
watchlist Created with Sketch. Add ARX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.